Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
97.44
+0.90 (0.93%)
At close: Nov 20, 2024, 4:00 PM
97.40
-0.04 (-0.04%)
Pre-market: Nov 21, 2024, 5:35 AM EST
Merck & Co. Revenue
Merck & Co. had revenue of $16.66B in the quarter ending September 30, 2024, with 4.35% growth. This brings the company's revenue in the last twelve months to $63.17B, up 6.51% year-over-year. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$63.17B
Revenue Growth
+6.51%
P/S Ratio
3.91
Revenue / Employee
$877,417
Employees
72,000
Market Cap
246.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher | 42.37B |
Abbott Laboratories | 41.22B |
Eli Lilly | 40.86B |
MRK News
- 1 hour ago - Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities - Business Wire
- 1 day ago - Merck Announces First-Quarter 2025 Dividend - Business Wire
- 1 day ago - Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade) - Seeking Alpha
- 1 day ago - Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again. - Barrons
- 2 days ago - Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation - Market Watch
- 2 days ago - Merck says Keytruda injection on par with approved IV version in trial - Reuters
- 2 days ago - Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Business Wire
- 3 days ago - Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November - Seeking Alpha